Recent clinical studies have reported the administration of the MEK1/2 inhibitor trametinib in patients with RASopathies associated with HCM (Andelfinger et al. 2019; Hribernik et al. 2023; Kiamanesh et al. 2024; Leegaard et al. 2022; Meisner et al. 2021; Mussa et al. 2021; Nakano et al. 2022). Here, MAP2K1 is linked to RASopathy.